Non Hodgkin Lymphoma Clinical Trial

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Summary

Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of relapsed, low-grade or follicular B-cell lymphoma
CD20-positive lymphoma
Progressive, measurable disease
Sign informed consent
3 weeks beyond standard therapy
Good performance status
Adequate hematologic, renal, and hepatic function

Exclusion Criteria:

Chronic lymphocytic leukemia
Lesions greater than or equal to 10 cm in diameter
CNS lymphoma
AIDS-related lymphoma
Pleural effusions or ascites secondary to lymphoma
Active, opportunistic infection
Serious nonmalignant disease
Prior investigational therapies, including prior anti-CD20 therapy
Recent major surgery

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 3

Estimated Enrollment:

150

Study ID:

NCT00168740

Recruitment Status:

Completed

Sponsor:

Biogen

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Arkansas for Medical Sciences
Little Rock Arkansas, , United States
City of Hope Natioal Medical Center
Duarte California, , United States
Scripps Memorial Hospital
La Jolla California, , United States
UCSD Stem Cell Laboratory
La Jolla California, , United States
Hoag Hospital
Newport Beach California, , United States
Sutter Cancer Center
Sacramento California, , United States
Sidney Kimmel Cancer Center
San Diego California, , United States
University of California, San Francisco
San Francisco California, , United States
Stanford University Medical Center
Stanford California, , United States
Kaiser Permanente Medical Center
Vallejo California, , United States
Rocky Mountain Cancer Center
Denver Colorado, , United States
Georgetown University Medical Center
Washington District of Columbia, , United States
Robert H. Lurie Cancer Center, Northwestern University
Chicago Illinois, , United States
University of Iowa General Hospital
Iowa City Iowa, , United States
University of Kentucky Medical Center
Lexington Kentucky, , United States
Louisiana State University
Shreveport Louisiana, , United States
University of Maryland Cancer Center
Baltimore Maryland, , United States
Michigan State University
East Lansing Michigan, , United States
St. Louis University Medical Center
St. Louis Missouri, , United States
Roswell Park Cancer Center
Buffalo New York, , United States
University of Rochester Cancer Center
Rochester New York, , United States
Fox Chase Cancer Center
Philadelphia Pennsylvania, , United States
University of Pittsburgh Medical Center
Pittsburgh Pennsylvania, , United States
The West Clinic, P.C.
Memphis Tennessee, , United States
Texas Oncology, P.A.
Dallas Texas, , United States
M.D. Anderson Cancer Center
Houston Texas, , United States
University of Texas Health Sciences Center
San Antonio Texas, , United States
University of Virginia
Charlottesville Virginia, , United States
Fred Hutchinson Cancer Research Center
Seattle Washington, , United States
Ottawa General Hospital
Ottawa Ontario, , Canada
Toronto-Sunnybrook Regional Cancer Center
Toronto Ontario, , Canada

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 3

Estimated Enrollment:

150

Study ID:

NCT00168740

Recruitment Status:

Completed

Sponsor:


Biogen

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider